Lancet 2:13001304 rskov C, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV, Holst JJ (1986) Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas
Overall, the market continues to demonstrate healthy momentum with broad-based performance across therapies
No documents were uploaded There are no additional links Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing
The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis
